- ￥350 - 4490
- Solarbio
- 北京
- IA7330
- 2026年01月20日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 保质期：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 英文名：
AST 487
- 库存：
现询
- 供应商：
北京索莱宝科技有限公司
- CAS号：
630124-46-8
- 规格：
50mg/25mg/10mg/5mg/1mg
| 规格： | 50mg | 产品价格： | ￥4490.0 |
|---|---|---|---|
| 规格： | 25mg | 产品价格： | ￥2403.0 |
| 规格： | 10mg | 产品价格： | ￥1490.0 |
| 规格： | 5mg | 产品价格： | ￥890.0 |
| 规格： | 1mg | 产品价格： | ￥350.0 |
| 基本信息 | |
| CAS | No.630124-46-8 |
| 英文名称 | AST 487 |
| 别名 | NVP-AST 487 |
| 分子式 | C26H30F3N7O2 |
| 分子量 | 529.56 |
| 溶解性 | Soluble in DMSO ≥10mg/mL |
| 纯度 | ≥98% |
| 外观(性状) | White to off-white Solid |
| 储存条件 | Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year |
| MDL | MFCD11983171 |
| SMILES | CCN1CCN(CC1)CC2=C(C=C(C=C2)NC(=O)NC3=CC=C(C=C3)OC4=NC=NC(=C4)NC)C(F)(F)F |
| InChIKey | ODPGGGTTYSGTGO-UHFFFAOYSA-N |
| InChI | InChI=1S/C26H30F3N7O2/c1-3-35-10-12-36(13-11-35)16-18-4-5-20(14-22(18)26(27，28)29)34-25(37)33-19-6-8-21(9-7-19)38-24-15-23(30-2)31-17-32-24/h4-9，14-15，17H，3，10-13，16H2，1-2H3，(H，30，31，32)(H2，33，34，37) |
| PubChem CID | 11409972 |
| 靶点 | RET |
| 通路 | Protein Tyrosine Kinase/RTK;Apoptosis |
| 背景说明 | AST 487 是一种 RET 激酶抑制剂，抑制 RET 自磷酸化，及下游效应器激活。 |
| 生物活性 | AST 487 is a RET kinase inhibitor with IC50 of 880 nM， inhibits RET autophosphorylation and activation of downstream effectors， also inhibits Flt-3 with IC50 of 520 nM.[1] |
| IC50 | IC50: 880 nM (RET)， 170 nM (KDR)， 790 nM (Flt-4)， 500 nM (c-Kit)， 520 nM (Flt-3)， 20 nM (Abl)[1] |
| In Vitro | A number of other kinases are also similarly inhibited by AST 487 (NVP-AST487) in the in vitro kinase assays， including KDR (IC50=170 nM)， Flt-4 (IC50=790 nM)， Flt-3 (IC50=520 nM)， c-Kit (IC50=500 nM)， and c-Abl (IC50=20 nM). AST 487 potently inhibits the growth of human thyroid cancer cell lines with activating mutations of RET but not of lines without RET mutations. Both GDNF/GFRα1 and persephin-induced calcitonin mRNA are markedly inhibited by coincubation with 100 nM of AST 487 in MTC-M cells[1]. AST 487 is a novel， mutant FLT3 inhibitor. AST 487 is tested in biochemical assays for inhibition of Flt-3 kinase activity. The Ki is determined to be 0.12 μM. Besides Flt-3， NVP-AST487 inhibits RET， KDR， c-Kit， and c-Abl kinase with IC50 values below 1 μM. Treatment of FLT3-ITD-Ba/F3 cells and D835Y-Ba/F3 cells with AST 487 potently inhibits cellular proliferation (IC50[2]. |
| 细胞实验 | After a single oral administration of 15 mg/kg of AST 487 to OF1 mice， a mean peak plasma level (Cmax) of 0.505±0.078 μM SE is achieved after 0.5 h. Similar levels of AST 487 are found in the plasma of mice up to 6 h after oral administration， with a Clast of 21±4 nM at 24 h. The oral bioavailability is calculated to be 9.7% with a t1/2 terminal elimination of 1.5 h[1]. |
| 细胞实验 | The trypan blue exclusion assay is used to determine proliferation of cells cultured in the presence and absence of NVP-AST 487. Cell viability is reported as percentage of control (untreated) cells， and data are presented as the average of 2 independent experiments， except where indicated. Error bars represent the standard error of the mean for each data point. Apoptosis of drug-treated cells is measured using the Annexin-V-Fluos Staining Kit. Cell-cycle analysis is performed[2]. |
| 动物实验 | Mice[1] Female athymic nude mice are kept under optimized hygienic conditions (maximum of 10 mice per Makrolon type III cage) with free access to food and water. Tumors are established by s.c. injection of 1×106 and 5×106 of NIH3T3-RETC634W and TT cells， respectively， in 100 μL of HBSS per mouse. Treatable tumors， i.e.， mean tumor volume of 100 mm3， developed within 10 days of NIH3T3-RETC634W cell injection， and within 20 days of TT cell injection. NVP-AST487 is given p.o.， once daily by gavage. The compound is formulated by dissolving the appropriate amount of powder in N-methylpyrrolidone/PEG300 (1:10 v/v). The mice are randomized into four treatment groups of eight mice each. The first three groups received daily oral administrations of NVP-AST487 at 50， 30， and 10 mg/kg， respectively， for 3 weeks. The fourth group received treatment with vehicle. Tumor growth and body weights are monitored twice weekly. Tumor volumes are determined according to the formula: length×diameter2×π/6. Tumors are collected and frozen in liquid nitrogen at the end of the efficacy study， 6 h after the last administration. |
| 激酶实验 | Glutathione S-transferase (GST)-fused kinase domains are expressed in baculovirus and purified over glutathione-sepharose. Kinase activity is tested by measuring the phosphorylation of a synthetic substrate [poly(Glu， Tyr)]， by purified GST-fusion kinase domains of the respective protein kinase in the presence of radiolabeled ATP; the ATP concentrations used are optimized within the Km range for the individual kinases. Briefly， each kinase is incubated under optimized buffer conditions in 20 mM of Tris-HCl (pH 7.5)， 1 to 3 mM of MnCl2， 3 to 10 mM of MgCl2， 10 μM of Na3VO4， 1 mM of DTT， 0.2 μCi [33P]ATP， 1 to 8 μM of ATP， 3 to 8 μg/mL of poly(Glu/Tyr， 4:1)， and 1% DMSO in a total volume of 30 μL in the presence or absence of NVP-AST487 for 10 min at ambient temperature. Reactions are terminated by adding 10 μL of 250 mM EDTA， and the reaction mixture is transferred onto an Immobilon polyvinylidene difluoride membrane. Filters are washed (0.5% H3PO4)， soaked in ethanol， dried and counted in a liquid scintillation counter. IC50s for AST 487 are calculated by linear regression analysis of the percentage inhibition[1]. |
| 数据来源文献 | [1]. Akeno-Stuart N， et al. The RET Kinase Inhibitor NVP-AST487 Blocks Growth and Calcitonin Gene Expression through Distinct Mechanisms in Medullary Thyroid Cancer Cells. Cancer Res. 2007 Jul 15;67(14):6956-64. [2]. Weisberg E， et al. Antileukemic effects of the novel， mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells. Blood. 2008 Dec 15;112(13):5161-70. |
| 单位 | 瓶 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验相关实验
GPI蛋白 本文提供了有关糖基磷脂酰肌醇（GPI，是许多蛋白以及病毒蛋白结合于膜上的锚点）的信息。同时，网站还提供了许多相关链接和资源。 GPI overview GPI proteins in chickens GPI proteins in Drosophila GPI in prion proteins Human GPI proteins: protectin (CD59) and homologous restriction factor (HRF
1. 前言 用蛋白质组学鉴别植物蛋白质经常遇到植物基因组序列数据量不够的问题。只有拟南芥和水稻被全部测序，这就意味着只有极少情况下可以专门使用质谱分析法（MS) 鉴别蛋白质，通常是用拟南芥这种模式植物 [ 1，2] 。在其他情况下，MS 测序可以同时用 Edman 测序 [ 3,4] 来测定氨基酸末端序列。另一种方法是在用光谱分析法测得末端序列后鉴别蛋白质，然后和已知序列的基因比对 [ 1，3，5，6] 。总的来说，用已知基因组序列的模式植物研究极大推进了植物蛋白
化酶电极法、总蛋白( TP) 双缩脲法、清蛋白(Alb) 溴甲酚紫法、镁(Mg) Calmagite 比色法,试剂及校准品由贝克曼公司提供;总胆红素( TB) 矾酸盐氧化法、直接胆红素(DB) 矾酸盐氧化法、丙氨酸氨基转移酶(AL T) 速率法、天门冬氨酸氨基转移酶(AST) 速率法、碱性磷酸酶(AL P) 速率法、γ-谷氨酰转肽酶(γ-GT) 速率法、淀粉酶(AMY) 法、胆固醇(CHO) 氧化酶法、三酰甘油( TG) CPO-PAP 法、肌酸激酶(CK) 速率法、乳酸脱氢酶(LDH) 速率法、尿酸
技术资料暂无技术资料 索取技术资料
IA7330 AST 487 蛋白酪氨酸激酶 索莱宝
￥350 - 4490
